| IRS | immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub... |
|---|---|
| IST | inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci... |
| BSR | basal skin resistance; blood sedimentation rate; bowel sounds regular; brain stimulation reinforceme... |
| LRMP | last regular menstrual period |
| reg | region; regular |
| insulin coma treatment | Rarely used treatment of major mental illness by means of hypoglycaemic coma induced by insulin. (05 Mar 2000) |
|---|---|
| insulin c-peptide | <investigation> A blood test which measures the amount of C-peptide in the blood. C-peptide is a byproduct of normal insulin production by the beta cells in the pancreas. Normal values are 0.5 to 3.0 ng/ml. Normal levels indicate that the body is still producing its own insulin. Low levels indicate that the pancreas is producing little or no insulin. Elevations can be seen in cases of insulinomas and islet of Langerhans tumours. (27 Sep 1997) |
| insulin dependent diabetes | A form of diabetes that requires the daily injection of the hormone insulin to maintain normal body chemistry. Avoidance of insulin in these patients will result in a severe metabolic derangement known as diabetic ketoacidosis. (27 Sep 1997) |
| insulin-dependent diabetes mellitus | A chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. The body is then not able to use the glucose (blood sugar) for energy. IDDM usually comes on abruptly, although the damage to the beta cells may begin much earlier. The signs of IDDM are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin, follow a diet plan, exercise daily, and test blood glucose several times a day. IDDM usually occurs in children and adults who are under age 30. This type of diabetes used to be known as juvenile diabetes, juvenile-onset diabetes, and ketosis-prone diabetes. (09 Oct 1997) |
| insulin hypoglycaemia test | A test to determine the completeness of vagotomy for peptic ulcer; after the surgical procedure is performed, insulin is administered to cause hypoglycaemia; if vagotomy is complete, the acid output from the stomach following administration of insulin is less than that before insulin administration; if the reverse if true, incomplete vagotomy is likely. Synonym: Hollander test. (05 Mar 2000) |
| insulin infusion systems | Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. (12 Dec 1998) |
| insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| insulin, lente | <chemical> Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension conisists of a mixture of crystals and amorphous material in a ratio of approximately 7:3. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin zinc (12 Dec 1998) |
| insulin-like activity | A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin. (05 Mar 2000) |
| insulin like growth factor | <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin. They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present). Insulin like growth factor I = somatomedin A = somatomedin C Insulin like growth factor II = MSA (Multiplication stimulating activity). Insulin like growth factor 1 is released from the liver in response to growth hormone. Acronym: IGF (18 Nov 1997) |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |
| insulin-like growth factor-binding protein 2 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth factor binding protein 3 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |